This study uses 3+3 clinical design.About 12-24 patients with advanced solid tumor malignancies are expected to be enrolled in this study. A total of four dose groups were set for dose escalation. Doses were administered every 21 days, with a DLT observation period of 21 days after the first dose. After completion of DLT assessment, the investigator decided whether to continue the treatment after the end of DLT assessment based on the subject 's tolerance and the safety profile of the dose group. Subjects may continue to receive dosing every 21 days if the investigator determines that the subject is benefiting from continued treatment. No more than 8 total doses were administered.
To evaluate the safety and tolerability of JCXH-212 injection in patients with advanced malignant solid tumors; to determine the maximum tolerated dose (MTD), and to evaluate the dose-limiting toxicity (DLT) of JCXH-212 injection.